Guilhem Richard

Guilhem Richard

Company: EpiVax Therapeutics

Job title: Chief Technology Officer


Immune Camouflaging in Tumors: Implications for Neoantigen Vaccines 11:00 am

JanusMatrix™, integrated in the Ancer® neoantigen discovery platform, is a specialized in silico tool used to distinguish effector from inhibitory neoantigens Ancer® analysis of tumors derived from nivolumab-treated melanoma patients reveals patterns consistent with immune camouflaging: lowered immunogenicity and increased tolerogenic signals Relevant neoantigen targets may be harder to identify once patients are treated with…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.